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Objective: Protein glutathionylation is considered an important post-translational modification in the pathogenesis of complex diseases.
The aim of this study was to examine whether hemoglobin (Hb) is modified by reduced glutathione (GSH) via oxidation of the thiol groups
present in diabetes and its associated microangiopathy and to determine whether oxidative imbalance has any correlation with
glutathionylated Hb (HbSSG) levels.
Methods: The study group consisted of a total of 130 subjects which included non-diabetic healthy control subjects (n = 30) and type 2
diabetic patients with (n = 53) and without (n = 47) microangiopathy. All subjects were assessed for glycemic and lipidemic status, while
diabetic subjects were also assessed for the diagnosis of retinopathy and nephropathy. RBC lysates from all the subjects were analyzed by
liquid chromatography/electrospray ionization-mass spectrometry (LC/ESI-MS) for HbSSG h-globin chains. Levels of GSH and
thiobarbituric acid substances (TBARS) levels were measured by spectrophotometric and fluorimetric methods, respectively.
Results: The positivity for HbSSG in diabetic subjects with microangiopathy was significantly higher (69%) compared to diabetics
without microangiopathy (22%) and control subjects (14%). In univariate regression analysis, HbSSG levels were significantly associated
with the duration of diabetes, HbA1c, and TBARS levels. GSH levels were negatively correlated (r = 0.57, P < 0.001) with HbSSG in
diabetic subjects. A significant inverse correlation (r = 0.42, P < 0.001) between the GSH levels and HbA1c levels was also seen in
diabetic subjects.
Conclusions: This is perhaps the largest LC-MS-based study to demonstrate that HbSSG levels are markedly increased in diabetic
subjects with microangiopathy. Since diabetic subjects also exhibited increased lipid peroxidation and decreased GSH levels, it appears that
enhanced oxidative stress may account for the increased HbSSG concentrations and altered reduction–oxidation (redox) signaling.
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Several experimental, epidemiological, and clinical
studies support the view that oxidative stress plays a
significant role in the development of vascular complica-
tions in diabetics [1,2]. The importance of reactive oxygen0009-9120/$ - see front matter D 2005 The Canadian Society of Clinical Chemis
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URL: www.mvdsc.org (M. Balasubramanyam).species (ROS) in the pathogenesis of diabetes and its
complications are well recognized and a considerable body
of evidence implicates ROS in defective cellular signaling
[3,4]. However, the molecular mechanisms by which ROS
alter cellular signaling are not well understood. Reactive
thiols on cysteine (Cys) residues of selected proteins are
among the most sensitive sites to be modified by ROS.
Oxidants react with these redox-sensitive thiols to form thiyl
radicals, which subsequently react with other thiols to form
mixed-disulfide bonds. In mammalian cells, glutathione is8 (2005) 892 – 899ts. All rights reserved.
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likely to bind to protein thiols to form mixed-disulfides, a
process termed S-glutathionylation [5,6].
Since a number of functionally critical proteins within
the cell possess accessible Cys residues, glutathionylation
may be considered an important post-translational modifi-
cation in the pathogenesis of complex diseases such as
diabetes. Therefore, we hypothesize that, under conditions
of increased oxidative stress and changes in glutathione
levels, many critical proteins are liable to undergo gluta-
thionylation in patients with diabetes and its associated
complications. In recent years, glutathionylated proteins
including HbSSG have been investigated as possible
biomarkers of oxidative stress using the HPLC or LC-MS
detection systems [6–10]. Since the blood concentrations of
glutathionylated proteins may reflect alterations in redox
signaling and oxidation status [10,11], in the present study,
we have used erythrocytes as a cellular model to test HbSSG
as a possible biomarker of increased oxidative stress.Methods
The study group was comprised of a total of 130
subjects, which included non-diabetic healthy control
subjects (n = 30) and type 2 diabetic patients with (n =
53) and without (n = 47) microangiopathy. The diabetic
subjects were selected from out-patients attending the Dr.
Mohans’ M.V Diabetes Specialties Centre (MVDSC), a
tertiary referral center for diabetes care at Chennai (formerly
Madras) in Southern India. Control subjects were recruited
from the on-going Chennai Urban Rural Epidemiological
Study (CURES), a population-based study in Chennai, the
details of which have been published elsewhere [12,13].
Details such as age, sex, and, in diabetes subjects, duration
of diabetes, and other details of diabetic therapy were
recorded; a complete clinical examination was conducted
for all subjects. Blood pressure was taken from the patient’s
right arm to the nearest 2 mm Hg with a mercury
sphygmomanometer (Diamond Deluxe Model, Pune, India)
while the patient was in the sitting position.
Biochemical and clinical parameter analysis
Biochemical analyses were done on a Hitachi-912
Autoanalyser (Mannheim, Germany) using kits supplied
by Boehringer Mannheim (Mannheim, Germany). Fasting
plasma glucose (glucose oxidase–peroxidase method),
serum cholesterol (cholesterol oxidase–peroxidase–amido-
pyrine method), serum triglyceride (glycerol phosphate
oxidase–peroxidase–amidopyrine method), high-density
lipoprotein cholesterol (HDL-C) (direct method), and serum
creatinine (modified kinetic method of Jaffe) were meas-
ured. Low-density lipoprotein cholesterol (LDL-C) was
calculated using the Friedewald formula [14]. Glycosylated
hemoglobin (HbA1C) was estimated by high-pressure liquidchromatography (HPLC) using the Variant machine (Bio-
Rad, Hercules, Calif., USA). Urine samples were collected
in the early morning after an overnight fast. Urine creatinine
was measured using Jaffe’s method. Urinary protein was
measured on spot urine by the sulfosalicylic acid technique
and expected 24 h protein excretion was calculated as
reported earlier [15]. Urine microalbumin concentration was
measured using commercially available immunoturbidomet-
ric assay kits from Randox (Randox, UK).
Definitions
Microangiopathy was diagnosed if either retinopathy or
nephropathy was present.
Nephropathy
Nephropathy was diagnosed if the patient had either
persistent proteinuria (150 mg/day) or microalbuminuria
(if albuminuria estimated by the albumin creatinine ratio
(ACR) exceeded 30 Ag/mg of creatinine) in the absence of a
urinary tract infection.
Retinopathy
Fundus photography was done to evaluate retinopathy in
the diabetic study subjects. The pupils were dilated using
one drop each of phenylepherine 10% and tropicamide 1%
into both eyes and drops were repeated until the best
possible mydriasis was obtained. A trained photographer
carried out four-field color retinal photography with a Zeiss
FF 450 plus camera using 35 mm color transparencies. The
photographs were graded against standard photographs of
the Early Treatment Diabetic Retinopathy Study (ETDRS)
grading system for severity of retinopathy as described
earlier [16]. Informed consent was obtained from all study
subjects and the institutional ethics committee approved the
study.
Measurement of glutathionylated hemoglobin (HbSSG)
For the estimation of HbSSG, fasting blood samples were
collected into vacutainer tubes containing acid citrate
dextrose (ACD) solution. Whole blood was centrifuged at
2000 rpm and the plasma and the buffy coat were removed.
The erythrocytes were washed three times in 0.9% NaCl and
centrifuged for 5 min after each wash. The packed
erythrocytes were then lysed in an equal volume of cold
water (Milli-Q; Millipore, France) and processed for mass
spectrometry analysis.
For electrospray experiments, an aliquot of the stock
solution was diluted 500-fold with distilled water and 10 AL
of this solution was injected into a single quadrupole mass
spectrometer (Hewlett Packard HP 1100 MSD series) with a
conventional electrospray ion source. The samples were
passed through a C18 reverse phase analytical column
(Zorbax, 4.6  150 mm). A linear gradient of acetonitrile
from 10–95% in 40 min was employed using distilled water
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phase. The flow rate was maintained at 0.2 mL/min. The
acquisition was set to full scan mode and the spectra were
acquired over the mass range 500 to 2000 m/z. Mass scale
calibration was done with horse heart apomyoglobin and
molecular mass information was obtained after deconvolut-
ing the multiply-charged species using the Chemstation
software supplied by the manufacturer. Deconvolution of
the charged states distinctively yielded masses (T2 Da) for
the Hba (15125 Da) and Hbh (15866 Da) chains,
glycosylated Hba (15,288 Da) and glycosylated Hbh
(16028 Da) and glutathionylated Hbh (16171 Da). The
glutathionyl Hbh concentration was expressed as the
percentage of its peak height ratio to that of total Hbh
(intact Hbh + glutathionyl Hbh + glycosylated Hbh) [6].
Measurement of glutathione level
Fasting blood samples were collected into vacutainer
tubes containing acid citrate dextrose (ACD) solution and
Hb concentrations were determined using a Sysmex
automated blood counter. Glutathione was estimated in cell
lysates (prepared by mixing 0.2 mL of packed cells to
1.8 mL of Na2EDTA) using metaphosphoric acid as the
precipitation agent. Samples were treated with 5,5V-dithio-
bis-2-nitro benzoic acid (DTNB), a compound readily
reduced by sulfhydryl compounds, forming a highly colored
compound which has a maximum absorbance at 412 nm
[17]; GSH concentrations were expressed as Amol/g Hb.
Lipid peroxidation
Plasma levels of malondialdehyde (MDA), a marker of
lipid peroxidation, were estimated by measuring TBARS via
fluorescence methodology [18]. Briefly, 200 AL of plasmaTable 1
Clinical and biochemical characteristics of the study subjects
Parameters Control subjects
(n = 30)
Age (years) 54 T 6.7
Duration (years) Nil
Body Mass Index (kg/m2) 25.8 T 6.6
Systolic BP (mm Hg) 120 T 18
Diastolic BP (mm Hg) 76 T 10
Fasting plasma glucose (mg/dL) 88 T 12.0
HbA1c (%) 5.8 T 0.5
Serum cholesterol (mg/dL) 158.9 T 36.2
Serum triglyceride (mg/dL) 110.4 T 69.4
HDL cholesterol(mg/dL) 47.2 T 14.0
LDL cholesterol (mg/dL) 113.6 T 33.7
Serum creatinine (mg/dL) 1.00 T 0.1
Glutathione (GSH) (Amol/g Hb)b 6.22 T 0.13
Thiobarbituric acid reactive
substances (TBARS) (nM/mL)b
5.90 T 0. 21
Values expressed as mean T SD.
a P < 0.05 compared to control group.
b Values expressed as mean T SEM.was precipitated with an equal volume of 8.1% SDS. The
reaction mixture was acidified with 20% acetic acid and
subsequently heated with thiobarbutric acid (TBA). It was
then allowed to form adducts with oxidative products for 1 h
at 95-C. After cooling, TBARS was extracted with butanol:
pyridine (15:1) and the fluorescence of the extract was read
at an excitation of 535 nm and emission of 553 nm.
1,1V,3,3V-tetramethoxypropane was used as the standard for
calculating the absolute MDA levels.
Statistical analysis
Statistical analysis was carried out on Windows based
SPSS package (version 4.0.1, Chicago, IL). Numbers were
expressed as mean T standard error. Comparisons between
groups were performed using the unpaired Student’s t test.
Two-tailed P < 0.05 was considered statistically significant.
Pearson correlation analysis was done between variables.
The Chi-square test was used to compare proportions.
Univariate regression and multiple logistic regression
analysis was done using HbSSG as the dependent variable
and factors such as age, duration of diabetes, HbA1c,
diastolic and systolic blood pressure, serum cholesterol,
triglycerides, HDL cholesterol, LDL cholesterol, erythro-
cyte GSH level, and plasma TBARS levels served as the
independent variables.Results
Table 1 shows the clinical characteristics of the study
groups. Diabetic subjects without microangiopathy had
higher systolic blood pressure compared to control
subjects. Diabetic subjects with microangiopathy had
significantly higher systolic and diastolic blood pressures,Diabetic subjects without
microangiopathy (n = 47)
Diabetic subjects with
microangiopathy (n = 53)
56 T 6.8 57 T 8.4
8.0 T 7.4 13.6 T 7.4
24.7 T 3.8 25.0 T 4.2
130 T 15a 137 T 14a
78 T 9 81 T 7a
127 T 45.0a 138.0 T 41.0a
7.7 T 2.5a 8.5 T 1.9a
167.3 T 40.3 169.2 T 38.7
129.6 T 56.5 156.7 T 81.3a
39.6 T 14.2 42.3 T 11.6
129.6 T 56.4 156.7 T 81.5a
1.03 T 0.10 1.09 T 0.45
5.14 T 0.17a 5.29 T 0.13a
9.14 T 0.53a 10.04 T 0.78a
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Fig. 1a shows an ESI mass spectrum of a non-diabetic
(control) subject’s hemoglobin. Deconvolution of the charge
states (transformed mass scale) distinctively yielded precise
masses for the a (15,125 Da; Mcalculated, 15,126 Da) and h
(15,866 Da; Mcalculated, 15,867 Da) chains. In hemoglobin
from a diabetic subject, the ESI mass spectrum revealed an
additional distinct mass at 16,171 Da, apart from the normal
globin chains detected at 15,125 Da (Hba) and 15,866 Da
(Hbh) (Fig. 1b). The 16,171 Da peak may be assigned to
HbSSG, formed by reaction of the free thiol group of
HbhCys93 with oxidized glutathione. The assignment of
HbSSG is reported in the literature [6]. To confirm our
HbSSG assignment, we have recorded the ESI mass spectra
of a normal Hb sample from a control subject to which
oxidized glutathione was added to 100 mM NH4HCO3
buffer, at a pH of 8.0, and incubated at 25-C for 2 h. UnderFig. 1. (a) ESI mass spectrum of hemoglobin chains from a control non-diabetic su
at 15,125 Da (Hba) and 15,866 Da (Hbh). (b) ESI mass spectrum of hemoglobin
additional mass at 16,171 Da (glutathionylated Hbh), separate from masses detecte
transformed mass scale of globin chains (inset) from a normal hemoglobin sample
HbSSG (16,171) appeared when hemoglobin was mixed with excess of GSSG in
spectrum and the transformed mass scale (inset) of a glutathionylated hemoglobi
(16,171) disappeared when hemoglobin was incubated at 25-C for 2 h in 100 mMthese conditions, in vitro glutathionylation occurs, yielding
3 polypeptide chains: a (15,125 Da), h (15,866 Da), and
glutathionylated h (16,171 Da) (Fig. 1c). In addition, when
the reducing agent, dithiothreitol (DTT), was added to
HbSSG, the 16,171 Da species disappeared (Fig. 1d),
further confirming our precise assignment of HbSSG.
The percentage of samples identified as positive for
HbSSG in diabetic subjects with microangiopathy (69%; 37/
53) was significantly higher (P < 0.05) compared to those
without microangiopathy (22%; 10/47) and control subjects
(14%; 4/30) (Fig. 2). In all HbSSG positive cases, we were
able to quantify the amount of HbSSG in terms of percentile
values (see methodology), and these values (mean T SE)
were significantly higher in diabetic subjects with (10.94 T
0.81%) and without (8.69 T 1.24%) microangiopathy
compared to controls (4.85 T 1.12%).
In diabetic subjects, univariate regression analysis
showed that after adjusting for age and sex, duration ofbject. The transformed mass scale (inset) shows two typical masses detected
chains in a diabetic subject. The transformed mass scale (inset) shows an
d at 15,125 Da (Hba) and 15,866 Da (Hbh). (c) ESI mass spectrum and the
after incubating with oxidized glutathione (GSSG). The peak representing
100 mM NH4HCO3, pH 8.0, and incubated at 25-C for 2 h. (d) ESI mass
n sample after reduction with dithiothreitol. The peak representing HbSSG
NH4HCO3 (pH 8.0) in the presence of 0.05 M dithiothreitol.
Fig. 4. Correlation of glutathionyl Hb (HbSSG) with GSH levels in diabetic
subjects (r = 0.57; P < 0.001).
Fig. 2. Percentile presence of glutathionylated hemoglobin in (a) control
subjects (14%), (b) diabetic subjects without (22%), and (c) with micro-
angiopathy (69%) (*P < 0.05 when compared with diabetic subjects
without microangiopathy and control subjects). The levels of glutathiony-
lated hemoglobin computed were (a) 4.85 T 1.12%, (b) 8.69 T 1.24%, and
(c) 10.94 T 0.81%.
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HbA1c (OR-2.08, 95% CI: 1.502–2.871; P < 0.0001), and
TBARS (OR-1.15, 95% CI: 1.032–1.270; P = 0.015) was
associated with HbSSG. Multiple logistic regression anal-
ysis revealed that duration of diabetes (OR-1.15, 95% CI:
1.047–1.269; P = 0.004) and HbA1c (OR-1.889, 95% CI:
1.248–2.858; P = 0.003) was significantly correlated with
HbSSG. The GSH levels in diabetic subjects with (5.29 T
0.13 Amol/g Hb) and without (5.14 T 0.17 Amol/g Hb)
microangiopathy were significantly (P < 0.001) lower
compared to control subjects (6.22 T 0.13 Amol/g Hb)
(Table 1). There was a significant inverse correlation (r =
0.42, P < 0.001) between the GSH and HbA1c levels in
diabetic subjects (Fig. 3). Interestingly, GSH values were
also negatively correlated (r = 0.57, P < 0.001) with the
HbSSG levels in diabetic subjects (Fig. 4). Levels of
TBARS, which are a measure of lipid peroxidation, were
significantly (P < 0.001) increased in diabetic subjects with
(10.04 T 0.78 nM/mL) and without microangiopathy (9.14 T
0.53 nM/mL) compared to control subjects (5.90 T 0. 21 nM/
mL) (Table 1). This measure of oxidative stress also
correlated negatively with GSH (r = 0.37, P = 0.001)Fig. 3. Correlation between HbA1c (%) and GSH (Amol/g Hb) levels in
diabetic subjects (r = 0.42, P < 0.0001).and positively with both HbA1c levels (r = 0.24, P = 0.025)
and fasting plasma glucose (r = 0.25, P = 0.018).Discussion
Currently, there is a growing awareness of the impor-
tance of oxidants as signaling molecules that directly impact
the function of tissues in a regulatory fashion by altering the
structure of proteinaceous cysteinyl thiols. Multiple modes
of protein–cysteine oxidation, such as S-thiolation, S-
nitrosylation, sulfenic acid, sulfinic acid, sulfenyl-amide
formation, reactive oxidized lipid derivates, and intra- and
intermolecular protein disulfides are already known to be
important in redox regulation [19–21]. The increasing
evidence of functional changes resulting from these
modifications as well as the growing number of proteins
glutathionylated both in vitro and in vivo [22] indicate a role
for glutathionylation in diabetes, where protein post-trans-
lational modifications might play an important role in the
maintenance and progression of disease pathogenesis.
Our work is significant for two reasons. First, this is
perhaps the largest LC-MS-based study to demonstrate that
HbSSG levels are markedly increased in diabetic subjects
with microangiopathy. Secondly, the fact that enhanced
oxidative stress may account for the increased HbSSG
concentrations was strongly supported by our results, which
showed that diabetic subjects also exhibited increased lipid
peroxidation and decreased GSH levels.
Increased oxidative stress in human diabetes has been
widely reported in the literature. Diabetic microangiopathy
correlated positively with lipid peroxidation levels [23,24]
and negatively with the GSH concentrations in erythrocytes
[25–30]. Sustained hyperglycemia facilitates the increased
production of ROS and impairment of the antioxidant
defense system leading to a drastic fall in GSH concen-
trations [31]. Niwa et al. [6] demonstrated increased HbSSG
in diabetic and hyperlipidemic patients, but they did not find
a correlation between HbSSG and HbA1c levels. However,
our study supports the findings of Al-Abed et al. [8], who
found that HbA1c levels correlated with HbSSG in diabetic
subjects. While increased oxidative stress (increased lipid
R. Sampathkumar et al. / Clinical Biochemistry 38 (2005) 892–899 897peroxidation and glutathione depletion) was observed in
diabetic subjects without microangiopathy, only 22% of
these patients were identified with HbSSG. This implies that
increased oxidative reactions could be early events in the
natural history of diabetes [32–34]. In contrast, the
formation of HbSSG may depend on the extent of altered
glutathione turnover (GSH synthesis, its recycling, and
utilization) [35]. Moreover, the extent of glutathionylation
may also be related to the duration of diabetes as indicated
in our study.
Apart from the increased lipid peroxidation and gluta-
thione depletion seen in Type 2 diabetic subjects with
microangiopathy, our study revealed the presence of HbSSG
in a remarkable 69% of the samples. Oxidative damage has
been implicated in the onset of diabetic eye complications in
which the decrease in free radical scavengers was shown to
be associated with the oxidation of vitreous and lens
proteins [36]. GSH is present in very high concentrations
(¨6 mM) in the lens of the eye and maintains the eye’s
transparency. Indeed, one of the earliest changes identified
in the diabetic rat lens, prior to opacification, was a fall in
glutathione levels [37,38]. Craghill et al. [39] have recently
identified a reaction site of glutathione mixed disulfide
formation on gamma crystallin S in the human lens, which
was claimed to play a role in cataract formation by
destabilizing crystallins. Similarly, glutathionylation has
also been shown to modify human beta A1/beta A3-
crystallins [40]. Since glutathionyl Hb exhibits high oxygen
affinity and low cooperativity [6], the increased glutathionyl
Hb concentrations in diabetic patients with microangiopathy
may result in a state of reduced tissue oxygen supply and
thereby may contribute to tissue hypoxia. In fact, retinal
hypoxia is accompanied by some pathological conditions
that may promote intraocular neovascularization [41].
Mesangial cells subjected to hyperglycemic conditions
exhibit elevated levels of intracellular MDA and reduced
GSH [42]. The reduced GSH levels were also accompanied
by decreased gene expression of gamma-glutamylcysteine
synthesis, the rate-limiting enzyme in de novo synthesis of
GSH. It appears that both in nephropathy and retinopathy,
the decrease in GSH levels may represent an imbalance of
redox signaling, favoring increased formation of GSSG and
subsequent protein glutathionylation cascades. Whether
these redox changes affect the functionality of the cells
and tissues specifically in the retina, lens, and kidney
requires further investigation.
Our study implies a role of protein glutathionylation in
the pathogenesis of diabetes and its associated complica-
tions. While the increased formation of HbSSG represents a
global change in the oxygen-carrying capacity of hemoglo-
bin, tissue-specific glutathionylation cascades may have
drastic cellular repercussions. In fact, the activities of
several signaling molecules including PP2A [43], Ras
[44], NFkB [45], RyR1 channels [46], PTP1B [47],
cAMP-PK [48], aldose reductase [49], mitochondrial com-
plex I [50], and SERCA [51] were reported to be modifiedas a consequence of glutathionylation. It is interesting to
note that alterations in these signals were reported in
defective insulin secretion in h cells, insulin sensitization
in peripheral tissues, and complication-related cell-injury
and tissue damage in diabetes [22].
Despite the precise importance of oxidative stress and
related signaling modifications in diabetes and its compli-
cations, studying oxidative stress in humans is limited by
the lack of reproducible methods. Although ROS have
been detected in vitro by electron spin resonance or by
chemiluminescence/fluorescence, these methods are not yet
applicable for routine clinical purposes. Our results suggest
that measurement of glutathionylated hemoglobin
(HbSSG), as assessed by LC-MS, can serve as a biomarker
of oxidative stress. This is perhaps one of the first studies
on HbSSG measurement in diabetic subjects with and
without microangiopathy trying to correlate HbSSG with
levels of GSH, TBARS, and glycemic and lipid markers.
Recent studies indicate that the use of LC-MS is a
sensitive and accurate technology for the study of
oxidative stress in human subjects. In support of this,
LC-MS based measurement of 8-iso-PGF2alpha has been
demonstrated as a sensitive and independent risk marker of
coronary heart disease [52]. In conclusion, our study
suggests that HbSSG could be used as a clinical marker of
oxidative stress and altered redox regulation in diabetes
and its microangiopathy.Acknowledgments
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